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CAPSULE SUMMARY: 52 
Primary or secondary plasma C3 deficiency due to mutations in C3 or in complement 53 
Factor I impairs memory B, but not T, cell differentiation, but does not preclude 54 
intracellular C3 fragment expression in lymphocytes. 55 
 56 
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To the Editor: 58 
 59 
Primary C3 deficiency is an extremely rare autosomal-recessive disease, with less 60 
than 50 families described worldwide. Plasma and intracellular C3 are considered BCR 61 
and TCR costimulators, respectively, but their contribution to lymphocyte biology 62 
remains obscure, particularly in humans. Reduced plasma C3 can be caused by primary 63 
C3 deficiency, due to loss-of-function (LOF) C3 mutations, but also by secondary C3 64 
deficiency or C3 consumption, due to gain-of-function (GOF) C3 mutations or to 65 
mutations in C3 regulators such as complement Factor I (CFI)1. We reasoned that 66 
comparing B and T cell differentiation and function in primary and secondary plasma 67 
C3 deficiency might help to understand the role of plasma and intracellular C3 in 68 
adaptive immunity. We report the immunological features of lymphocytes from nine 69 
individuals with low plasma C3 belonging to six families with mutations causing 70 
primary or secondary C3 deficiency and, in some cases, chronic kidney disease stages 71 
1-3 (see Figure E1, A and Tables E1 and E3 in the Online Repository).  72 
 73 
To study whether reduced plasma C3 levels could affect lymphocyte 74 
differentiation, patients, healthy carriers (HC) and healthy donors (HD) were 75 
immunophenotyped and compared for several T and B cell subsets, including those 76 
representing successive differentiation and effector subsets. Absolute lymphocyte 77 
numbers were always within normal ranges (not shown). T lymphocyte differentiation 78 
was essentially normal, and no significant differences, except for increased Tfh cell 79 
frequency, were detected when individuals above (HC+HD) or below (patients) 40 80 
mg/dL plasma C3 (Fig E1, B in the Online Repository) were compared (see Fig E2, in 81 
the Online Repository). In contrast, impaired naïve to memory B cell differentiation was 82 
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observed in both primary and secondary plasma C3-deficient patients (Fig 1, A), with 83 
increased naïve (CD19+IgD+CD27–) B cells, and reduced unswitched 84 
(CD19+IgD+CD27+) and switched (CD19+IgD–CD27+) memory B cells. Such changes 85 
were statistically significant when plasma C3 levels were below the 40 mg/dL threshold 86 
(Fig 1, B).  87 
 88 
B cell regulation by complement involves antigen opsonization by C3d and 89 
recognition through CD21/CR2, a component of the B cell co-receptor2, which lowers 90 
the threshold for B cell activation3. To determine a possible role of circulating C3-91 
opsonizing fragments in the generation of memory B cells, we analyzed the correlation 92 
between plasma C3 levels and B or T cell subpopulations in our cohort. The results 93 
showed a statistically significant positive correlation of plasma C3 levels with the 94 
frequency of unswitched memory B cells, and negative correlation with that of naïve B 95 
cells, but not with total B cells (Fig 1, C). A non-significant positive correlation was 96 
found also with switched memory B cell levels. In contrast, none of the T cell 97 
subpopulations analyzed correlated with plasma C3 levels (see Fig E2, C in the Online 98 
Repository). Although impaired memory B cell differentiation has been reported in a 99 
GOF plasma C3-deficient patient4, here we demonstrate in a larger cohort that reduced 100 
plasma C3 levels, whether primary or secondary, results in a selective defect in the in 101 
vivo differentiation of memory B, but not T, lymphocytes. 102 
 103 
To explore whether the defect in memory B cell development caused by C3 104 
deficiency was associated to altered T or B cell function, PBMC were studied. Ex vivo T 105 
and B cell function, measured as proliferation in response to mitogens (see Fig E3 in the 106 
Online Repository), or in vivo B cell function, measured as immunoglobulin or vaccine-107 
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specific antibody levels (see Table E2 in the Online Repository), were mostly normal in 108 
our cohort, despite their low plasma C3 levels. Although C3 deficiency has been 109 
associated with recurrent bacterial infections1 and decreased proliferation against 110 
specific recall antigens, neither primary nor secondary plasma C3-deficient patients in 111 
our cohort (or other's5) showed clinical features suggestive of severe T or B cell defects. 112 
However, our findings may be clinically relevant to improve patient management in 113 
countries where health conditions or vaccinations are below Western standards.   114 
 115 
Both B and T lymphocytes contain intracellular C3 fragments6. Indeed, it was 116 
shown that cathepsin-L-cleaved intracellular C3 was required for T cell homeostasis 117 
and, upon TCR engagement, increased and participated in Th1 responses. Hence, we 118 
generated pure T and B cell lines from our cohort and analyzed their intracellular C3 119 
content by flow cytometry using specific mAb against two C3-associated neo-epitopes 120 
(see Fig E4 in the Online Repository). The results showed that all tested cell lines 121 
derived from primary or secondary plasma C3-deficient patients, above or below 40 122 
mg/dL plasma C3, expressed intracellular C3 fragments at HD levels (see Fig 2, A, left 123 
and Fig E5, A in the Online Repository). In addition, intracellular C3a was increased 124 
after TCR activation of C3-deficient T cell lines (see Fig E5, B). These observations are 125 
in line with previously unexpected published data6 and prompted a closer analysis of 126 
plasma C3 levels by Western blot and ELISA (Fig 2, A, right). The results showed that 127 
even primary, and expectedly secondary, C3-deficient plasmas have very low levels of 128 
C3 proteins, which may thus accumulate in cellular compartments and allow 129 
intracellular detection. Of note, the presence of iC3b/C3dg fragments in cells from 130 
factor I (fI)-deficient patients suggested fI-independent cleavage in lymphocytes.  131 
 132 
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Intracellular localization studies revealed that C3a and iC3b/C3dg fragments 133 
showed different subcellular locations, with iC3b/C3dg, but not C3a (which has 134 
previously shown to be located in the lysosomes in T cells6), found predominantly 135 
associated to the cis-Golgi (Fig 2, B and C). These results suggest a differential 136 
intracellular location of the cleaving enzymes generating these complement fragments7. 137 
Interestingly, T cell lines from primary plasma C3 deficiency showed accumulation of 138 
all C3 tested fragments in several subcellular compartments, particularly in lysosomes, 139 
which may impair exocytosis of C3 (Fig 2, C, right). 140 
 141 
Taken together, these results indicate that although intracellular C3 expression in 142 
lymphocytes occurs despite severe plasma C3 deficiency, it cannot replace plasma C3 143 
for memory B cell differentiation. The present data support our previous suggestion that 144 
human C3 deficiency is always leaky to some extent and that complete combined intra- 145 
and extracellular C3 (or C5) deficiency may not be viable in humans8. A mechanism 146 
bridging innate and adaptive immunity thus emerges connecting B cell co-receptor 147 
recognition of C3 fragments, in a concentration-dependent manner, and memory B cell 148 
differentiation. We hypothesize that reduced plasma C3 impairs the generation of C3 149 
activating/opsonizing fragments such as C3dg/C3d. In turn, BCR co-activation through 150 
CD21/CR2 would be impaired, hampering sufficient signaling for the generation of 151 
memory B cells. Note that this would not affect the generation of antigen-specific 152 
antibodies later on (Fig E6). See a Supplemental Discussion in the Online Repository. 153 
 154 
In summary, despite the small size of the cohort, we report a side-by-side study of 155 
B and T cell features in the very rare conditions of C3 and fI deficiencies. Our results 156 
show that plasma C3 is essential for the development of memory B, but not T, 157 
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lymphocytes in a plasma C3 level-dependent fashion, and demonstrate that very low 158 
plasma C3 levels do not preclude the expression of intracellular C3 fragments in 159 
lymphocytes.  160 
 161 
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FIG 1. B lymphocyte immunophenotype. A, B cell subset frequencies compared with normal  percentiles 247 
(n=10 HC + patients vs 12 HD). Symbols as in Fig E1, B. B, B cell subsets (mean+SD) of individuals 248 
below (patients) or above (HD + HC) the 40 mg/dL plasma C3 thresholdn (gray area in C). ns: non-249 
significant; **p <0.01. C, Correlation analysis (Pearson’s r) of B cell subsets and plasma C3 levels. Solid 250 
lines are best-fit linear regressions, dashed lines are 95% confidence intervals.  251 
 252 
FIG 2. C3 detection in T cell lines and plasma from C3-deficient patients. A, Left, Intracellular C3 253 
fragments in single cell lines from donors above or below the 40 mg/dL plasma C3 threshold (flow 254 
cytometry). Data are mean±SD of GEO-MFI relative to isotype controls (dashed lines). ns: non-255 
significant; Right, Extracellular C3 detection by Western blot (α chain) vs ELISA and nephelometry 256 
(mg/dL means or range) in plasma from primary (MS, missense and FS, frameshift) and secondary (MS) 257 
C3-deficient patients. B, Subcellular T cell colocalization of C3 fragments with cis-Golgi (confocal 258 
microscopy x60 using one C3a- and two iC3b/C3dg-specific mAb, scale bars 5 µm). C, Statistical 259 
analysis of C3 fragment colocalization with several subcellular compartments (mean+SD; only r > 0.5 260 
(dashed horizontal lines) were considered; p<*0.05, **0.01, ***0.001). 261 
 262 
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1
ONLINE REPOSITORY MATERIAL 1 
 2 
METHODS 3 
 4 
Donors, complement profile, genetic diagnosis and lymphocyte isolation  5 
Ten different individuals (nine with low plasma C3 levels, seven below 40 mg/dL 6 
and medium/long-term clinically diagnosed disease, see Table E3) belonging to six 7 
different families with primary (due to loss-of-function, LOF, C3 mutations) or 8 
secondary (due to gain-of-function, GOF, C3 mutations, or due to LOF complement 9 
Factor I or CFI mutations) plasma C3 deficiency were studied (Fig E1). In all cases, 10 
age- and sex-matched healthy donors (HD) were included (n ≤ 18). Plasma C3 levels 11 
and genetic data are summarized in Table E1. Healthy carriers (HC) and patients were 12 
classified according to their primary or secondary C3 deficiency, their LOF/GOF 13 
mutated or wild type (WT) alleles for C3 or CFI (WT/LOF; LOF/LOF; WT/GOF), but 14 
also by an arbitrary 40 mg/dL threshold for very low plasma C3 levels observed in all 15 
patients with clinical features (Fig E1, B). All HC and HD had plasma C3 ≥ 40 mg/dL. 16 
In figure legends, full red and red/white symbols denote homozygous or heterozygous 17 
individuals, respectively, with plasma C3 < 40 mg/dL and clinical features. Black/white 18 
symbols identify HC. Triangles and rhombuses identify individuals with mutations in 19 
C3 or CFI, respectively.  20 
C3 and CFI mutations screening and genotyping were performed as described E1, 21 
E2
. Plasma C3 levels were measured by nephelometry or ELISA. Peripheral blood 22 
mononuclear cells (PBMC) were isolated from peripheral blood (EDTA) by density-23 
gradient centrifugation (Ficoll Paque Plus, GE Healthcare).  24 
All samples were obtained after written informed consent from the donors or their 25 
guardians, and all studies were performed according to the principles expressed in the 26 
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2
Declaration of Helsinki and approved by the Institutional Research Ethics Committees 27 
of the hospitals involved. 28 
 29 
Case reports (see Table E3 for further details) 30 
C3.1.II:1 is a 18-year-old membranoproliferative glomerulonephritis (MPGN) 31 
type I primary plasma C3-deficient patient of Pakistani origin diagnosed at age 9, born 32 
to consanguineous parents. From age 12 to 15 he suffered from IgA-negative cutaneous 33 
episodes of vasculitis and knee arthralgia resembling Henoch-Schönlein Purpura (HSP). 34 
He also suffered one severe episode of pneumonia with pleural effusion that required 35 
draining. Despite signs of microhematuria and microalbuminuria, renal function was 36 
preserved. Renal biopsies showed C3-negative linear glomerular deposits with intense 37 
immunofluorescence staining (4/4) for IgM, C4 and C1q and intermediate (3/4) for IgA, 38 
IgG, kappa and lambda chains, as well as focal mesangial deposits weakly staining for 39 
IgA, IgG, C4 and C1q. C3.1.I:1 is his HC father with low plasma C3 levels. 40 
 41 
C3.2.II:1 is a 13 year-old Spanish MPGN immunofluorescence-negative primary 42 
plasma C3-deficient patient diagnosed at age 1, who presented macroscopic hematuria 43 
and proteinuria in the nephritic range but no signs of renal dysfunction or infectious 44 
disease. As observed in C3.1.II:1, he presented recurrent HSP-like IgA-negative 45 
vasculitis in the lower limbs. He received a complete immunization with two doses of 46 
Prevenar® before 2 years of age and showed high pneumococcus-specific IgG titers 47 
after a dose of Pneumococcal polysaccharide vaccine (PPV-23, Pneumovax®23) at 8 48 
years of age. He also displayed non-immune hemolytic anemia associated to 49 
splenomegaly. Enzymatic disorder and paroxysmal nocturnal hemoglobinuria was ruled 50 
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3
out. Immunofluorescence staining of renal biopsies was repeatedly negative. C3.2.I:2 is 51 
his HC mother with low plasma C3 levels.  52 
 53 
C3.3.II:2 is a 40 year-old Spanish MPGN type I secondary plasma C3-deficient 54 
patient diagnosed at age 23. When he was 15 years old, he suffered a sepsis episode 55 
with generalized HSP and renal insufficiency, presently persistent reduced C3 levels in 56 
serum, proteinuria and mild hematuria. A renal cortex biopsy showed a high proportion 57 
of sclerotized glomeruli. Non-sclerotized glomeruli showed a lobulated morphology and 58 
mesangial proliferation, endocapillar hypercellularity and capillary wall thickening. 59 
Direct immunofluorescence revealed intense granular C3 staining in the mesangium and 60 
peripheral regions and weakly intense staining of IgM, C1q, kappa chains and IgA in 61 
peripheral subendothelial regions.  62 
 63 
C3.4.I:1 is a 49 year-old healthy secondary plasma C3-deficient Spanish man 64 
with mild proteinuria and microhematuria diagnosed at age 45. 65 
 66 
CFI.1.II:1 is 39 year-old woman with secondary plasma C3 deficiency due to a 67 
homozygous mutation in CFI reported previously E2, E3. She was diagnosed at 23, but 68 
she debuted at 16 years of age with a meningococcal septicemia coincident with 69 
menstruation. From age 22, she developed up to 20 monthly recurrent episodes of acute 70 
meningitis around the perimenstrual period. Her younger sister aged 30 (CFI.1.II:4) has 71 
the same genotype and secondary plasma C3 deficiency. 72 
 73 
CFI.2.II:2 is a 53 year-old woman with secondary plasma C3 deficiency due to a 74 
homozygous mutation in CFI E2 diagnosed at age 19. She suffered several episodes of 75 
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otitis during childhood and was diagnosed of juvenile chronic polyarthritis and HSP at 76 
11. She suffered meningococcal meningitis at 17 and meningococcal pneumonia at 19 77 
years of age. Two of her siblings have a clinical history of infectious diseases (otitis, 78 
septic arthritis and lymphocytic meningitis). She is presently asymptomatic. 79 
 80 
Extracellular flow cytometry 81 
The following mAbs were used: CD3 (A07746), CD4 (A07751, A07752), CD8 82 
(A07756, A07758), CD19 (A07771), and CD45RA (IM0584U) from Beckman Coulter; 83 
CD27 (555440), CD31 (555446), IgD (555779), and TCRγδ (333141) from BD 84 
Biosciences; TCRαβ (306717) from BioLegend. FACSCalibur instrument (BD 85 
Biosciences); and CellQuestPro (BD Biosciences) and FlowJo (Tree Star) software 86 
were used for the analysis. 87 
Gating strategy for B immunophenotype: CD19+ lymphocytes were analyzed for 88 
IgD+CD27– (naïve), IgD+CD27+ (unswitched) and IgD–CD27+ (switched) cell 89 
distributions.  90 
Gating strategy for T immunophenotype: lymphocytes were analyzed for CD3+, 91 
αβ
+ or γδ+ cell distribution; CD3+ lymphocytes were analyzed for CD4+ and CD8+. 92 
Gating strategy for CD4+ T cell subsets: CD4+CD45RA+CD31+ (recent thymic 93 
emigrants or RTE), CD4+ CD45RA+CD31– (central naïve or CN), 94 
CD4+CD25loCD127hiCXCR5–CD45RA+ (naïve), CD4+CD25loCD127hiCXCR5–95 
CD45RA– (memory), CD4+CCR7+CD45RA– (central memory), CD4+CCR7–CD45RA– 96 
(effector memory), CD4+CD25hiCD127lo (Treg) and CD4+CD25loCD127hiCXCR5+ 97 
CD45RA– (follicular helper T or Tfh)E4. Th1 (CXCR3+CCR6–), Th2 (CXCR3–CCR6–), 98 
Th17 (CXCR3–CCR6+) and Th1/Th17 (CXCR3+CCR6+) subsets were analyzed within 99 
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the subpopulation of memory CD4+ T cells. Analysis and gating strategy for CD8+ T 100 
cell subsets was performed as previously described E4, E5. 101 
 102 
Proliferation in response to mitogens and antibody titers 103 
PBMC were stained with carboxyfluorescein succinimidyl ester (CFSE, from 104 
Molecular Probes) and cultured in RPMI-1640 supplemented with 10% FBS for 5 days 105 
after stimulation with 1 µg/mL plate-coated anti-CD3 (UCHT-1, OKT3; eBioscience), 5 106 
µg/mL Phaseolus vulgaris leucoagglutinin (PHA), 10 ng/mL phorbol myristate acetate 107 
(PMA) and 1 µM ionomycin, 8 µg/mL Phytolacca americana pokeweed (PWM) 108 
(Sigma-Aldrich) or 10 ng/mL superantigens (Staphylococcal Enterotoxin B or E, SEB, 109 
SEE; Toxin Technology, Inc.). CFSE dilution was analyzed by flow cytometry as 110 
reported E6. Vaccine-specific serum antibody titers were determined with ImmunoCAP® 111 
Rc208 kit (for anti-Tetanus toxoid IgG levels) (Phadia, Uppsala, Sweeden); Human 112 
anti-Diphteria Toxoid IgG EIA kit (Binding Site, Birmingham, UK), Rubella ELISA 113 
IgG kit (Vircell, Granada, Spain), Varicella ELISA IgG kit from Vircell, Enzygnost® 114 
anti-Measles virus IgG kit (Siemens, Marburg, Germany). Anti-pneumococcal IgG 115 
titers were measured with an in-house ELISA using Pneumo23® polysaccharide 116 
pneumococcal vaccine as antigen and HRP-labelled goat anti-human IgG as detection 117 
antibody. 118 
 119 
Generation of transformed T and B cell lines 120 
Human T cell lymphotropic virus type 1 (HTLV-1)-transformed T cell lines, 121 
which have been reported to synthesize higher intracellular C3 than resting or activated 122 
primary T cells E7, were generated as reported E8, and maintained in RMPI-1640 123 
supplemented with 10% FBS, 1% L-glutamine, 1% Antibiotic-Antimycotic (Gibco), 124 
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and 100 IU/mL recombinant human IL-2 (provided by Craig W. Reynolds, Frederick 125 
Cancer Research and Development Center, NCI, NIH, Frederick, Maryland, USA). B 126 
cells were transformed as described E9 and maintained in RMPI-1640 supplemented 127 
with 20% FBS, 1% L-glutamine, 1% Antibiotic-Antimycotic (Gibco). 128 
 129 
Intracellular flow cytometry  130 
Cells were fixed with 2% paraformaldehyde and permeabilized with 0.5% 131 
saponin, or using commercial kits (Cytofix/Cytoperm, 554722 from BD Biosciences; 132 
Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent, 00-133 
5521-00 from eBioscience). Primary and secondary antibody dilutions and washings 134 
were performed in saponin-containing buffer. Intracellular C3 detection was performed 135 
by flow cytometry using several mouse anti-human C3-specific monoclonal antibodies 136 
(mAbs) (Fig E4): SIM320.12.2.1 (iC3b/C3dg1) and SIM320.12.3.1 (iC3b/C3dg2) were 137 
produced in house and detect a fI-cleavage dependent neo-epitope of the C-terminal 138 
domain of both iC3b and C3dg fragments (IgG1 isotype); clone 2991 (ab11873 from 139 
Abcam, IgG1 isotype) detects a C3 convertase-dependent C3a neo-epitope. CD46 140 
(555948 from BD Biosciences) or CD19 (A07771, PE-Cy5 from Beckman Coulter) 141 
were used as positive controls for T or B cell lines, respectively. For purified mAb 142 
several PE-conjugated goat anti-mouse IgG secondary antibodies were used: goat 143 
F(ab’)2 anti-mouse IgG (H+L) (731856 from Beckman Coulter or 12-4010-87 from 144 
eBioscience) and goat anti-mouse IgG (550589, BD Biosciences). 145 
 146 
ELISA and Western blot  147 
96-well plates were coated with a rabbit anti-human C3 antibody (produced in 148 
house) in PBS at 4°C.  After blockage with Tris-Tween 1% BSA for 1 hour at room 149 
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temperature (RT), serial dilutions in Tris-Tween 1% BSA of plasma samples were 150 
added and incubated for 1 hour at RT. C3 was detected using a mouse anti-human C3 151 
monoclonal antibody (produced in house, clone SIM27) for 1 hour at RT followed by a 152 
peroxidase-labeled goat anti-mouse incubation for 30 minutes at RT. For detection we 153 
used OPD substrate. The reaction was stopped with 10% sulfuric acid. Absorbance was 154 
measured at 492 nm. Purified human C3 was used for the calibration curve. All samples 155 
were tested in duplicate. 156 
Human C3 was detected by Western blot after SDS-PAGE of plasma samples 157 
under reducing conditions using a polyclonal rabbit anti-human C3 antibody (produced 158 
in house). 159 
 160 
Confocal microscopy  161 
For subcellular localizations analysis of C3a and iC3b/C3dg fragments, cells were 162 
fixed and permeabilized using Foxp3/Transcription Factor Fixation/Permeabilization 163 
Concentrate and Diluent (00-5521-00 from eBioscience), and blocked with 1X 164 
Permeabilization Buffer (00-8333-56 from eBioscience) with  1% hIgG + 10% FBS 165 
(Gibco). Primary and secondary antibody dilutions and staining washes were also 166 
performed in 1X Permeabilization Buffer. C3a and iC3b/C3dg fragments were detected 167 
using the same mAb as for intracellular flow cytometry (Fig 2, B). Subcellular 168 
compartments were detected using rabbit anti-human polyclonal antibodies (from 169 
Thermo-Fisher Scientific): GM130 (Cis-Golgi, PA1-077), Trans-Golgi Network 46 170 
(Trans-Golgi, PA1-1069), EEA1 (Early endosome, PA1-063A) and Lamp1 (Lysosome, 171 
PA1-654A). Alexa Fluor® 488-conjugated goat anti-Mouse IgG (H+L) Superclonal™ 172 
and Alexa Fluor® 555-conjugated goat anti-Rabbit IgG (H+L) Superclonal™ were used 173 
as secondary antibodies (A28175 and A27039, from Invitrogen). Mouse IgG1 174 
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(eBisocience) and rabbit IgG (Abcam) were used as isotype controls. Cells were 175 
mounted using ProLong® Gold with DAPI (P36935 from Molecular Probes) and images 176 
(represented as maximum intensity projections from Z-stacks) were obtained in the 177 
Center for Cytometry and Fluorescence Microscopy of Complutense University with an 178 
Olympus FV1200 Confocal Microscope and analyzed with Fiji/ImageJ (NIH, USA). 179 
Pearson’s correlation coefficients Rcoloc from Fiji/ImageJ were used for statistical 180 
analysis, and colocalization was accepted when r > 0.5 (dashed lines in Fig 2, C).  181 
For intracellular C3a expression analysis after TCR activation, cells were 182 
analyzed before or after activation in 48-well plates coated with 2.0 µg/mL mAb against 183 
CD3 (OKT3 clone, purified from a hybridoma in Kemper’s Lab), for 36 hours. Cells 184 
were fixed and permeabilized using Cytofix/Cytoperm (554722 from BD Biosciences), 185 
and blocked with 1X Perm/Wash (554723 from BD Biosciences) with 10% FBS 186 
(Gibco). Primary and secondary antibody dilutions and staining washes were also 187 
performed in 1X Perm/Wash buffer. C3a and iC3b/C3dg fragments were detected using 188 
the same mAb as for intracellular flow cytometry, above and Fig E5); Alexa Fluor® 189 
488-conjugated rabbit anti-mouse IgG (H+L) from Invitrogen (A11059) was used as 190 
secondary antibody. Cells were mounted with VECTASHIELD HardSet Antifade 191 
Mounting Medium with DAPI (H-1500, from Vector Laboratories, Inc.) and images 192 
(represented as maximum intensity projections from Z-stacks) were obtained in the 193 
King’s College London Nikon Imaging Centre by confocal microscopy with an A1R Si 194 
Confocal Microscope (x100 objective) and analyzed with NIS Elements software 195 
(NikonTM, Surrey, UK). 196 
 197 
Statistical analysis 198 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Jiménez-Reinoso et al., 9 
 
 
9
Results are shown either as scatter dot plots compared with the normal 5th, 50th 199 
and 95th percentiles in boxes, or as mean + or ± standard deviation (SD). Two-tailed 200 
Student’s t test, one-way ANOVA with Tukey’s multiple comparison post-hoc test, and 201 
Pearson’s correlation coefficient method with two-tailed p-value, were performed in the 202 
latter using GraphPad Prism (La Jolla, CA), and significance was considered only when 203 
p-values were < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001). 204 
 205 
 206 
ONLINE REPOSITORY DISCUSSION 207 
 208 
Clinical relevance 209 
The memory B cell development impairment shown in both primary and 210 
secondary C3-deficient patients (Fig 1) did not cause an equivalent functional 211 
impairment in vitro (Fig E3) or in vivo (Table E2), and it did not correlate with the 212 
severity of the kidney disease (Table E3). Correspondingly, despite reports of recurrent 213 
bacterial infections in some primary plasma C3-deficient patients1, 4, E10, our cohort, as 214 
well as other’s 5, did not show clinical features suggestive of severe B cell defects, such 215 
as bacterial, sinopulmonary infections, or gastrointestinal infections by Giardia lamblia 216 
or rotavirus. Other examples of impaired B cell transit from naïve to memory stages 217 
with normal levels of specific antibodies have been reported, for instance in human 218 
CD21/CR2 (the C3 fragment receptor) deficiencyE11. In contrast, human deficiencies of 219 
other components of the B cell co-receptor, such as CD19 or CD81, are associated with 220 
both impaired memory B cell development and defective antibody responsesE12-14, 221 
suggesting discrete roles for each co-receptor chain in B cell differentiation (see 222 
graphical abstract in Fig E6). European vaccination guidelines were used in our cohort, 223 
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which was carefully followed-up by top-notch specialists. This may explain the absence 224 
of overt clinical correlates of B-cell dysfunction, which may be clinically more relevant 225 
for the management of complement deficiency patients in countries where health 226 
conditions or vaccinations are below Western standards. 227 
It could be argued that some compensatory mechanism could partly replace the 228 
lack of plasma C3 in patients to provide signals that support normal T and B 229 
lymphocyte responses. However, we find such compensation unlikely because C3 230 
deficiency affects all complement activation pathways (classical, lectin and alternative) 231 
as C3 activation is the central step where all converge. Indeed, the alternative 232 
complement activation pathway supports up to 80% of all complement activationE15, 233 
and immunoglobulin deposits, as found in most patients in our cohort (Henoch–234 
Schönlein purpura, membranoproliferative glomerulonephritis, Table E3), indicate a 235 
defect in immune complex clearance, which depends on the classical complement 236 
pathway. 237 
 238 
Impact of C3 mutations  239 
We report immunological features of patients carrying LOF C3 mutations causing 240 
primary C3 deficiency (p.T56TfsX16 and p.G561D), and GOF C3 mutations and LOF 241 
CFI mutations causing secondary C3 deficiency (p.W552C and p.R1042GE16 for C3, 242 
and p.C247GE2 and p.A258TE2 for CFI , Fig E4, B and Table E1), which were leaky in 243 
all cases (Fig 2, A, right), perhaps explaining intracellular C3 detection. LOF C3 244 
mutations reduce plasma C3 levels by generating misfolded proteins, likely degraded. 245 
GOF C3 dominant mutations4, E16 reduce plasma C3 levels by generating abnormal 246 
alternative pathway C3 convertases (C3bBb), which cannot be inactivated and thus 247 
consume the normal C3 encoded by the normal allele. LOF CFI mutations reduce C3 248 
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levels by preventing C3b degradation, allowing C3bBb to consume normal C3. A 249 
graphical abstract summarizes these mechanisms (Fig E7).  250 
The LOF C3 mutations resulted in distinct biochemical features (Fig 2, A, right): 251 
the frameshift p.T56TfsX16 mutation is very severe but allowed for minute amounts of 252 
a slightly larger α C3 protein (normal size is 110 kDa), whereas the missense p.G561D 253 
mutation seemed less severe and its normal-sized product was cleaved into C3b (101 254 
kDa α’ chain). However, in all cases, intracellular C3 fragments were detected (Fig 2 255 
and Fig E5), although slightly less in primary C3-deficient T, but not B, cells (Fig 2, A). 256 
In addition, C3 fragments accumulated in degradation compartments, which could 257 
impair C3 exocytosis (Fig 2, C, right and graphical abstract in Fig E8). These data 258 
strongly support our previous contention that complete (combined intra- and 259 
extracellular) C3 (or C5) deficiency may not exist in humans8. 260 
Taken together, our data indicate an essential role for plasma C3 in the 261 
development of memory B, but not T, lymphocytes, and support disparate regulation of 262 
plasma C3 and intracellular C3 content in lymphocytes.  263 
 264 
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ONLINE REPOSITORY FIGURE LEGENDS 326 
 327 
 328 
 329 
FIG E1. Cohort of studied individuals. A, Pedigrees from the six families studied; 330 
mutations in C3 or complement Factor I (CFI) are shown below each family tree. 331 
Arrows indicate studied individuals (red for patients, black for healthy carriers, HC) in 332 
each family. B, All patients showed plasma C3 levels below 40 mg/dL (right), which 333 
was considered a threshold for further analyses. HD, healthy donors. 334 
 335 
FIG E2. T lymphocyte immunophenotype analysis. A, T cell subset distribution 336 
compared with normal 5th, 50th and 95th percentiles (boxes; n=17 HD). Each symbol 337 
represents an individual from a single experiment. B, Statistical analysis comparing T 338 
cell subsets (mean+SD) of individuals below (patients) or above (HD + HC) the 40 339 
mg/dL plasma C3 threshold; ns: non-significant; *p <0.05. C, Correlation between T 340 
cell subsets and plasma C3. r: Pearson’s correlation coefficient. Solid lines are the best 341 
fit after linear regression; dashed lines are their 95% confidence intervals. Gray areas 342 
mark the < 40 mg/dL plasma C3 range. Symbols as in Fig E1, B. 343 
 344 
FIG E3. Lymphocyte proliferation in response to different stimuli. A, Scatter dot plots 345 
of patients and HC T (CD3+) and B (CD19+) proliferation in response to the indicated 346 
stimuli measured as % CFSE– cells after 5 days compared with normal 5th, 50th and 95th 347 
percentiles (boxes; n=18 HD). NA: non-activated. B, Statistical analysis comparing 348 
lymphocyte responses (mean+SD) of individuals below (patients) or above (HD + HC) 349 
the 40 mg/dL plasma C3 threshold: ns: non-significant. 350 
 351 
FIG E4. A, Diagram of native C3 (top) and its fragments and plasma or vesicular 352 
enzymes involved, including the binding sites in C3a, iC3b and C3dg of the indicated 353 
mAb (clones between brackets). B, The mutations in plasma C3-deficient patients from 354 
Table E1 are shown in native C3. 355 
 356 
FIG E5. Intracellular C3 analysis in T cell lines from plasma C3-deficient patients. A, 357 
Representative intracellular C3a, iC3b/C3dg and CD46 or CD19 expression in T (left) 358 
and B (right) lymphoblastoid cell lines derived from the indicated primary or secondary 359 
plasma C3-deficient patients compared to isotype controls (gray histograms). B, 360 
Intracellular C3a expression using mAb 2991 in T cell lines from primary plasma C3-361 
deficient patients (C3.1.II:1 and C3.2.II:1) and a HD, after TCR activation for 36 hours, 362 
measured by confocal microscopy (magnification x100).  363 
 364 
FIG E6. Differential effects of primary deficiencies of B cell co-receptor components 365 
or ligands in B cell differentiation and antibody synthesis. 366 
 367 
FIG E7. Impact of primary and secondary plasma C3 deficiencies due to LOF/GOF C3 368 
and LOF CFI mutations in extracellular C3 activation. 369 
 370 
FIG E8. Subcellular accumulation of C3 fragments in vesicular traffic degradation 371 
compartments of primary C3-deficient T cells (right) compared to HD T cells (left), 372 
combining our results and previous data6, E17. Red arrows identify biosynthetic-secretory 373 
pathways; blue arrows denote retrieval/recycling pathways; green arrows identify 374 
endocytic pathways. C3aR, C3a receptor; CTSL, cathepsin-L. 375 
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 376 
ONLINE REPOSITORY TABLES 377 
 378 
TABLE E1. Genetic data, plasma C3 and serum fI levels. 
Family Mutation Plasma C3 (mg/dL)§ 
fI 
(%) 
Code ID Plasma C3 deficiency† Gene Exon Nucleotide Amino acid 
Type‡ 
≥ 40 < 40¶  
a) b) 
C3.1 I:1 HC 
C3 2 c.168_169del p.T56TfsX16 FS 
C3 WT/LOF 65  ND 
 II:1 Primary C3 LOF/LOF  < 6 76.2 
C3.2 I:2 HC 
C3 13 c.1682G>A p.G561D MS 
C3 WT/LOF 40  ND 
 II:1 Primary C3 LOF/LOF  9 88.0 
C3.3 II:2 Secondary C3 13 c.1656G>C p.W552C MS C3 WT/GOF  17 ND 
C3.4* I:1 Secondary C3 24 c.3124C>G p. R1042G MS C3 WT/GOF  < 6 ND 
CFI.1* I:2 HC 
CFI 5 c.739T>G p.C247G MS 
CFI WT/LOF 97 
 
ND 
 II:1 Secondary CFI LOF/LOF  19 0.1 
 II:4 Secondary CFI LOF/LOF  17 0.0 
CFI.2* II:2 Secondary CFI 5 c.772G>A p.A258T MS/Sp CFI LOF/LOF  33 2.4 
Normal local ranges for plasma C3 or serum fI are 75-135 mg/dL or 77-115 % of normal human serum, respectively; values in bold are below normal 
range. Subject identification (ID) as in Fig E1, patients in bold. *Reported previouslyE2, E16.  †HC: healthy carrier; ND, not determined. ‡: a) By effect 
on structure: FS, frameshift; MS, missense; Sp, splicing; b) By effect on protein function: WT, wild type; LOF, loss-of-function; GOF, gain-of-
function. §Mean values of 2-6 determinations (nephelometry). ¶All with clinical symptoms. 
 379 
  380 
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 381 
TABLE E2.  Serum immunoglobulins and vaccine-specific antibodies. 
Family  Immunoglobulins  Bacteria  Virus 
Code 
 
ID 
 
Age* 
 
 
IgG 
 
IgA 
 
IgM 
 
 
Strep. 
pneumoniae 
Tetatuns 
toxoid 
Diphteria 
toxoid  
Rubella 
 
Varicella 
 
Measles 
 
C3.1 I:1 45  ND ND ND  14.0 16.2 0.1  ─   
 II:1 13  845 203 97  4.7 26.3 1.3  ─   
C3.2 I:2 40  ND ND ND  24.7 6.9 0.4     
 II:1 8  1630 315 116  88.0 8.5 0.5     
C3.3 II:2 35  746 230 64  ND ND ND  ND ND ND 
CFI.1 I:2 55  ND ND ND  3.6 13.9 0.3     
 II:1 36  1130 121 233  5.4 30.1 0.2     
 II:4 26  852 226 111  11.7 30.4 0.9     
CFI.2 II:2 50  1050 333 110  6.5 3.1 0.03     
Normal range 
 
725-1900 
mg/dL 
50-340 
mg/dL 
45-280 
mg/dL  
> 0.1  
µg/mL 
> 2.4 
µg/mL 
> 0.01 
IU/mL      
Identification (ID) as in Fig E1 (patients in bold). *At date of analysis. : positive. ─: negative. ND, not determined. 
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TABLE E3. Clinical and immunological features of plasma C3-deficient patients. 
Code Plasma C3 
deficiency 
Age (years) Main renal 
pathology 
Renal 
dysfunction 
stage‡  
Other pathologies Infections§ Current  
condition 
% Memory B cells¶ 
AD* PA† Unswitched Switched  
C3.1.II:1 Primary 9 18 MPGN I 1 HSP 
Arthralgia 
Pneumonia (x2) 
 
Normal renal 
function 
Mild proteinuria 
2.40 1.70 
C3.2.II:1 Primary 1 13 MPGN I 1 HSP 
Hemolytic anemia 
Chronic hemolysis 
Splenomegaly 
Streptoccocal 
pharingytis 
Viral meningitis, 
B19 parvovirus  
Normal renal 
function 
Chronic  hemolysis 
Splenomegaly 
8.70 6.50 
C3.3.II:2 Secondary 23 40 C3G 3 HSP 
Hypertension 
Hypercholesterolemia 
Septicaemia 
Pneumonia 
Proteinuria 
Mild hematuria 
8.40 7.90 
C3.4.I:1 Secondary 45 49 
- 1 - - Asymptomatic 6.54 22.40 
CFI.1.II.1 Secondary 23 39 
- - 
- Meningococcal 
septicaemia 
Meningococcal 
meningitis (x20) 
Asymptomatic 4.20 3.90 
CFI.1.II.4 Secondary 14 30 
- - 
- - Asymptomatic 3.70 4.70 
CFI.2.II:2 Secondary 19 53 
- - 
HSP 
Chronic juvenile 
arthritis 
Meningococcal 
meningitis 
Pneumococcal 
pneumonia  
Asymptomatic 5.67 12.88 
MPGN I: membranoproliferative glomerulonephritis. C3G: C3 glomerulopathy. HSP: Henoch-Schönlein purpura. *At diagnosis; †present age; ‡CKD (Chronic Kidney 
Disease) stage: min 1 - max 5. No correlation was found with memory B cell levels, not shown; §bacterial, viral, other; number of infections are marked between brackets; ¶ 
Normal ranges (5th-95th percentiles) for memory B cells: 8.6-28.4 % unswitched and 11.4-32.6 % switched. Bold means out of range.   
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